Pathfinder Cell Therapy, Inc.
PFND · OTC
9/30/2015 | 6/30/2015 | 3/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $71 | $28 | $13 | $53 |
| G&A Expenses | $138 | $116 | $191 | $163 |
| SG&A Expenses | $138 | $116 | $191 | $165 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $209 | $144 | $204 | $218 |
| Operating Income | -$209 | -$144 | -$204 | -$218 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$80 | -$78 | -$72 | -$75 |
| Pre-Tax Income | -$289 | -$222 | -$276 | -$293 |
| Tax Expense | $80 | $78 | $72 | $75 |
| Net Income | -$369 | -$300 | -$348 | -$368 |
| % Margin | – | – | – | – |
| EPS | -0.001 | -0 | -0.001 | -0.001 |
| % Growth | -50% | 20% | 16.7% | – |
| EPS Diluted | -0.001 | -0 | -0.001 | -0.001 |
| Weighted Avg Shares Out | 667,161 | 667,161 | 667,161 | 667,161 |
| Weighted Avg Shares Out Dil | 667,161 | 667,161 | 667,161 | 667,161 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $80 | $78 | $72 | $75 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$208 | -$143 | -$203 | -$218 |
| % Margin | – | – | – | – |